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Abstract
Intravenous leiomyomatosis is an unusual smooth muscle neoplasm with quasi-malignant 
intravascular growth but a histologically banal appearance. Herein, we report expression and 
molecular cytogenetic analyses of a series of 12 intravenous leiomyomatosis cases to understand 
better the pathogenesis of intravenous leiomyomatosis. All cases were analyzed for expression of 
HMGA2, MDM2 and CDK4 proteins by immunohistochemistry based on our previous finding of 
der(14)t(12;14)(q14.3;q24) in intravenous leiomyomatosis. Seven of 12 (58%) intravenous 
leiomyomatosis cases expressed HMGA2, and none expressed MDM2 or CDK4. Co-localization 
of hybridization signals for probes from the HMGA2 locus (12q14.3) and from 14q24 by 
interphase fluorescence in situ hybridization (FISH) was detected in a mean of 89.2% of nuclei in 
HMGA2-positive cases by immunohistochemistry, but in only 12.4% of nuclei in negative cases, 
indicating an association of HMGA2 expression and this chromosomal rearrangement 
(p=8.24×10−10). Four HMGA2-positive cases had greater than two HMGA2 hybridization signals 
per cell. No cases showed loss of a hybridization signal by interphase FISH for the frequently 
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deleted region of 7q22 in uterine leiomyomata. One intravenous leiomyomatosis case analyzed by 
array comparative genomic hybridization revealed complex copy number variations. Finally, 
expression profiling was performed on three intravenous leiomyomatosis cases. Interestingly, 
hierarchical cluster analysis of the expression profiles revealed segregation of the intravenous 
leiomyomatosis cases with leiomyosarcoma rather than with myometrium, uterine leiomyoma of 
the usual histological type, or plexiform leiomyoma. These findings suggest that intravenous 
leiomyomatosis cases share some molecular cytogenetic characteristics with uterine leiomyoma, 
and expression profiles similar to that of leiomyosarcoma cases, further supporting their 
intermediate, quasi-malignant behavior.
INTRODUCTION
Smooth muscle tumors arising from the uterus range from benign uterine leiomyomata to 
malignant leiomyosarcoma and include a variety of tumors with unusual growth patterns. 
uterine leiomyoma is the most common tumor of the female reproductive tract (1), and 
approximately 25–40% of uterine leiomyomata have non-random tumor-specific cytogenetic 
abnormalities (2, 3). In addition to “usual type” uterine leiomyoma, clinically benign 
histologic variants are recognized including atypical (a.k.a. bizarre, pleomorphic, or 
symplastic), plexiform, and cellular leiomyomata (4–6). In contrast to uterine leiomyoma, 
leiomyosarcoma is rare, has an aggressive clinical behavior, complex cytogenetic and 
genomic rearrangements, and is histologically distinguishable from uterine leiomyoma by 
the presence of coagulative tumor necrosis, severe nuclear or cytological atypia, and elevated 
mitotic activity (7–9). In addition to the histologic spectrum of smooth muscle tumors, 
tumors resembling uterine leiomyoma at both gross and microscopic levels but presenting in 
unusual locations with quasi-malignant behavior include intravenous leiomyomatosis, 
disseminated peritoneal leiomyomatosis, and benign metastasizing leiomyoma.
intravenous leiomyomatosis is a rare entity characterized by intravascular nodular masses of 
histologically benign smooth muscle cells growing in uterine and pelvic veins, and 
sometimes extending into the inferior vena cava and chambers of the right heart (10–13). 
Intravenous leiomyomatosis occurs most commonly in women in the fifth decade, 
characteristically presenting with abnormal uterine bleeding or pain due to concomitant 
presence of uterine leiomyoma. If the intravenous leiomyomatosis mass extends along the 
inferior vena cava, venous return to the right heart becomes obstructed, and patients can 
present with findings of hemodynamic compromise, such as dyspnea, syncope, congestive 
heart failure, or even sudden death (14). Clinical examination usually reveals an enlarged 
uterus or a pelvic mass. On pathologic examination, multiple myometrial masses are 
typically associated with worm-like plugs within parametrial vessels. Despite the presence 
of extensive intravascular involvement, patients with intravenous leiomyomatosis typically 
have long term survival after successful removal of the tumor, and most patients have an 
unremarkable clinical course with a relatively low risk of pelvic recurrence or distant 
metastasis (10). The lung is the most common site of subsequent spread (15, 16).
Although the etiology of intravenous leiomyomatosis remains to be elucidated, two theories 
have been advanced. One theory suggests that intravenous leiomyomatosis originates from 
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the vessel wall, while the other purports that intravenous leiomyomatosis invasion into the 
vessel wall occurs subsequent to extension from a uterine leiomyoma (17). Analyzing 
molecular genetic events underlying intravenous leiomyomatosis provides an opportunity to 
gain understanding of its pathogenesis.
The presence of a karyotype with a der(14) t(12;14)(q15;q24) in our two previously 
published intravenous leiomyomatosis cases (Table 1) correlating with the t(12;14)(q15;q24) 
cytogenetic subgroup in uterine leiomyoma suggests a potential pathogenetic relationship 
between intravenous leiomyomatosis and uterine leiomyoma based on dysregulation of the 
non-histone chromatin factor HMGA2 at 12q14.3 (18, 19). Given the proximity of MDM2 
and CDK4 at 12q15 and 12q14.1, respectively, to the HMGA2 locus, and their roles in 
various mesenchymal tumors (20–23), alterations in their expression might underlie 
molecular mechanisms in intravenous leiomyomatosis. Because uterine leiomyoma and 
intravenous leiomyomatosis are histologically similar and usually present concomitantly in a 
patient, analyzing the common cytogenetic alterations of uterine leiomyoma in intravenous 
leiomyomatosis might provide insights into the biology of intravenous leiomyomatosis and 
its relationship with uterine leiomyoma.
Herein, a series of 12 cases of intravenous leiomyomatosis was analyzed for 
immunohistochemical expression of HMGA2, MDM2, and CDK4, and interphase FISH 
analysis was performed to assess co-localization of probes at the HMGA2 and 14q24 loci. In 
addition, presence of an interstitial deletion of 7q was assessed because the deletion of 7q22 
is one of the most common cytogenetic abnormalities in uterine leiomyoma (24). Finally, 
expression profiles of three cases of intravenous leiomyomatosis with myometrium, uterine 
leiomyoma, histological variants of leiomyomata (cellular, atypical and plexiform) and 
leiomyosarcoma were compared by hierarchical clustering analysis and differential gene 
expression was analyzed between intravenous leiomyomatosis cases and a set of nine uterine 
leiomyoma cases with t(12;14) (25).
MATERIALS AND METHODS
Cases diagnosed as intravenous leiomyomatosis were retrieved from archives of the Brigham 
and Women’s Hospital (nine cases) and Baystate Medical Center (three cases) under IRB 
approved protocols. Hematoxylin and eosin-stained slides were reviewed to confirm the 
diagnoses based upon published criteria (26–28). Two additional intravenous 
leiomyomatosis samples (CHTN 19480 and 52343) were obtained from the Cooperative 
Human Tissue Network (http://www.chtn.nci.nih.gov/) for expression profile analysis.
Immunohistochemical Analysis
Immunohistochemistry was performed following pressure cooker pretreatment for antigen 
retrieval. Intravenous leiomyomatosis tissue sections were subsequently incubated with 
primary anti-HMGA2 polyclonal antibody (59170AP, Biocheck Inc., Foster City, CA), and 
MDM2 (IF2 clone, EMD Chemicals, San Diego, CA) and CDK4 (DCS-31 clone, Invitrogen, 
Carlsbad, CA) antibodies for 40–60 minutes at 25° C. Following rinsing with Tris buffer 
solution, bound antibody was detected with the Envision Plus/Horseradish Peroxidase 
system (Dako, Carpinteria, CA). Tissue was then incubated using the Envision Plus 
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secondary antibody for 30 minutes followed by diaminobenzidine for five minutes. 
Appropriate positive and negative controls were stained in parallel. Staining for HMGA2, 
MDM2 and CDK4 proteins was scored as 0 (no nuclear staining), 1+ (< 5% of nuclei 
positive), 2+ (5% to 25% of nuclei positive), 3+ (26% to 50% of nuclei positive), or 4+ 
(>50% of nuclei positive).
GTG-banded Karyotyping
Discarded tumor tissue from Case 1 was obtained aseptically immediately following 
resection, during intra-operative pathology consultation, was disaggregated for short-term 
culture, and chromosome analysis performed as previously described (29). GTG-banded 
karyotypes of Cases 2 and 3 were reported previously (Table 1) (18, 19). Case 3 had two 
masses (pelvic ST02-165 and adnexal ST02-166) with different cellular ratios of the same 
mosaic karyotypes (18). Specimens for Cases 4–12 were not available for tissue culture, and 
thus, karyotyping was unable to be performed.
Array Comparative Genomic Hybridization
DNA was available only for Case 3 (ST02-166) (18). Array comparative genomic 
hybridization (aCGH) compared DNA obtained from Case 3 to DNA from a pooled female 
DNA sample (Promega, Madison, WI) as previously described (30).
Metaphase Fluorescence In Situ Hybridization
Metaphase fluorescence in situ hybridization (FISH) analysis was performed for Case 1. 
Bacterial artificial chromosome (BAC) clones were selected using the University of 
California Santa Cruz Genome browser (http://genome.ucsc.edu) (February 2009 assembly). 
BAC DNAs were isolated following a standard protocol consisting of alkaline lysis, 
neutralization, and ethanol precipitation (Qiagen, Valencia, CA). BAC clone RP11-299L9 
located at the 5′ end of HMGA2, including exons 1 and 2 (nucleotides 
66,049,805-66,225,867, hg19), was labeled with SpectrumGreen (Abbott Molecular, Des 
Plaines, IL), and RP11-427K2 located at the 3′ end of HMGA2, including exons 4 and 5 
(nucleotides 66,323,478-66,481,711, hg19), was labeled with SpectrumOrange (Abbott). 
Metaphase FISH analyses of Cases 2 and 3 were reported previously (Table 1) (18, 19).
Interphase Fluorescence In Situ Hybridization
FISH was performed on interphase nuclei of intravenous leiomyomatosis tissue sections for 
assessing the presence of t(12;14) and del(7)(q22). Tissue sections of Case 3 were not 
available for interphase FISH. Interphase FISH analysis was unsuccessful for two cases: 
Case 6 in the t(12;14) study and Case 11 in the del(7)(q22) study. Four-micron sections of 
formalin fixed paraffin embedded intravenous leiomyomatosis tissue on glass slides were 
baked overnight at 56° C, deparaffinized by three immersions in xylene, followed by 
dehydration in 100% alcohol. Air dried slides were immersed in 100 mM Tris-base, 50 mM 
EDTA (pH 7.0) buffer for 45 minutes at 100° C, rinsed in 1x phosphate buffered saline 
(PBS) for 5 minutes, and treated twice with 100 μl of Digest-All (Invitrogen) at 37°C for 20 
minutes. Next, slides were rinsed in 1x PBS, fixed in 10% buffered formalin at room 
temperature for one minute, and rinsed again in 1x PBS. Slides were then dehydrated in an 
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alcohol series of 70%, 90%, and 100% and air-dried prior to hybridization. 12–16 μg of 
fluorochrome-labeled BAC probes were applied to sections on the air-dried slides, followed 
by denaturation in the HYBrite apparatus (Abbott) at 95°C for three minutes and overnight 
incubation at 37°C. Hybridized slides were washed in 0.5x SSC at 72°C for five minutes 
followed by rinsing three times in PBS-Tween 0.025% and air drying in the dark before 
counterstaining with DAPI II anti-fade solution (Abbott). Ninety to 100 interphase nuclei 
were evaluated per case. For each nucleus, numbers of red and green hybridization signals 
were counted. To detect presence of the t(12;14), co-localization of hybridization signals 
(yellow signal or direct juxtaposition of red and green signals) for BAC probes 
RP11-366L20, located at the 3′ end of HMGA2 including exons 4 and 5 (nucleotides 
66,246,519-66,425,264, hg19) (SpectrumGreen), and RP11-195L19, located at 14q24.1 
(nucleotides 68,341,567-68,510,240, hg19) (SpectrumOrange), was assessed. For detection 
of del(7)(q22), loss of the hybridization signal of BAC probe RP11-374E17, located at 
7q22.3, and presence of the control probe TelVysion 7p SpectrumGreen Probe/Hyb Set 
(Abbott), located within 300 kb of the end of 7p, were evaluated.
Statistical analysis comparing interphase FISH for t(12;14) and immunohistochemistry 
status of HMGA2 was performed using the two-sample t-test included in SYSTAT version 
12.01.01 (SYSTAT Software, Chicago, IL.).
RNA Expression Profiling
RNA isolated from Case 3 and two additional samples obtained from the Cooperative 
Human Tissue Network (CHTN 19480 and 52343) were analyzed using standard protocols 
and statistical methods as previously described (25, 31–33). These three intravenous 
leiomyomatosis expression profiles were compared to those previously reported for 
myometrium, uterine leiomyoma, histological variants of leiomyomata (cellular, atypical 
and plexiform) and leiomyosarcoma (31–33). In addition, differential gene expression was 
analyzed between intravenous leiomyomatosis cases and a set of nine previously reported 
uterine leiomyomata with t(12;14) (25) to gain an understanding of the quasi-malignant 
behavior of intravenous leiomyomatosis despite their similar cytogenetic characteristics. 
Independent assessment of the differentially expressed genes by quantitative PCR could not 
be performed due to insufficient RNA.
RESULTS
Immunohistochemistry analysis of HMGA2 revealed that seven of 12 (58%) cases of 
intravenous leiomyomatosis (Cases 1–7) showed strong, diffuse (4+) nuclear staining and 
the remaining five (Cases 8–12) were negative (0 staining) (Fig. 1 and Table 2). Expression 
of MDM2 or CDK4 proteins by immunohistochemistry was negative in all 12 cases 
examined.
Results of GTG-banded karyotype and metaphase FISH analyses of Case 1 were determined 
to be 45,XX,del(12)(q?14q?15),hsr(14)(q2?1),-22[7].ish del(12)(q14.3q14.3)(5′HMGA2-,
3′HMGA2-),hsr(14)amp(3′HMGA2) (Table 1, Fig. 2), interpreted as a der(14) with 
amplification of the 3′ HMGA2 region and an interstitial deletion of 12q14.3 involving the 
entire HMGA2. This result is further supported by interphase FISH results consistent with a 
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der(14) with amplification of the 3′ HMGA2 region and absence of 3′ HMGA2 region-
hybridization to the del(12) (in Fig. 2, the 3′HMGA2 probe is labeled with SpectrumOrange 
in metaphase FISH and with SpectrumGreen in interphase FISH). Of note, this case had 
plexiform histological features (Fig. 1A).
Similar chromosomal aberrations with der(14) have been reported for Cases 2 and 3 in our 
previous publications (18, 19). The GTG-banded karyotype of Case 2 had a der(14)t(12;14) 
(q15;q24) in all metaphases, and Case 3 had a mosaic karyotype including both 
der(14)t(12;14) (q15;q24) and t(12;14) (q15;q24). Of note, both Cases 1 and 2 had 
monosomy 22 (Table 1). Metaphase FISH analysis for Cases 2 and 3 revealed three 
hybridization signals for HMGA2 on two apparently structurally normal chromosomes 12 
and on the der(14) in the breakpoint region with a pattern indicating the 12q breakpoint 
occurred 5′ (centromeric) to HMGA2 (Table 1) (18, 19). aCGH was able to be performed 
only for Case 3 (ST02-166) and the results correlated with the complex karyotype with 
multiple aneuploidies, in addition to a loss of material on chromosome 14 (14q24->14qter), 
confirming replacement of a chromosome 14 with a der(14)t(12;14) (Table 3).
Based on the high frequency of these chromosomal aberrations in intravenous 
leiomyomatosis, interphase FISH was performed using BAC probes for HMGA2 (at 
12q14.3) and 14q24.1 loci on intravenous leiomyomatosis cases (Fig. 3 and Table 2). In 
Case 1, HMGA2 amplification was detected in 90/100 nuclei and co-localization of signals 
was found in 82/100 nuclei in parallel to metaphase FISH and GTG-banded karyotype 
analyses (Fig. 2). In Case 2, three hybridization signals for HMGA2 were found in 69/100 
nuclei and co-localization of signals was detected in 94/100 nuclei consistent with the 
previously reported karyotype and metaphase FISH analyses revealing two copies of 
chromosome 12 and one copy of the der(14)(12;14) (19). 89.2% (95% confidence interval: 
83.8–94.6%) of nuclei on immunohistochemically HMGA2-positive tumors analyzed by 
interphase FISH (5/7) showed co-localization of chromosome 12 and 14 signals, while only 
12.4% (95% confidence interval: 8.8–16.0%) of nuclei on HMGA2-negative tumors 
analyzed by interphase FISH (5/5) showed co-localization of the probes. The correlation of 
immunohistochemistry and FISH status was significant at p=8.24×10−10. Of note, evidence 
of more than two hybridization signals for HMGA2 was found only in one additional case; 
20/100 interphase nuclei in Case 5 showed three hybridization signals for HMGA2. This 
level was appreciably lower than that observed in Case 2 (69/100), and may represent 
mosaicism. Overall, four of six (66.6%) HMGA2-positive intravenous leiomyomatosis cases 
analyzed by FISH had three or more signals for HMGA2, an indication of the presence of an 
unbalanced der(14) rather than a balanced t(12;14). It should, however, be noted that the 
interphase FISH results with only co-localization of chromosome 12 and 14 signals without 
multiplication of HMGA2 signal may still be due to the presence of a der(14), if there were 
concomitantly an interstitial deletion of chromosome 12 similar to the del(12) seen in Case 1 
(Fig. 2).
Interphase FISH for deletion of 7q22 was also performed to assess whether the most 
commonly observed chromosomal aberration reported in uterine leiomyoma (24) also 
presents as a nonrandom chromosomal abnormality in intravenous leiomyomatosis. None of 
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10 cases able to be evaluated was interpreted to have a del(7)(q22) based on loss of 
hybridization for the probe.
Hierarchical cluster analysis was performed to compare expression profiles of three 
intravenous leiomyomatosis cases with previously reported leiomyosarcomas, myometria, 
uterine leiomyomata, and histological variants of uterine leiomyoma (cellular, atypical and 
plexiform) (31–33). Intravenous leiomyomatosis cases clustered together on a single node 
along with a case of metastatic leiomyosarcoma (LMS 906), despite the presence of t(12;14)
(q15;q24) and HMGA2 over-expression in one plexiform leiomyoma case (ST06-015F) and 
one uterine leiomyoma case (ST99-240) (Fig. 4). To investigate further the difference 
between intravenous leiomyomatosis cases and uterine leiomyoma with t(12;14), 
differentially expressed genes (p<0.05) were assessed between intravenous leiomyomatosis 
cases and an independent set of nine t(12;14) uterine leiomyoma cases which had previous 
transcriptional profiling (25) (Fig. 5). Twenty-four out of 33 genes found to be significant 
for differential expression by this analysis are reported to be up or down-regulated in cancer 
as potential oncogenes or tumor suppressor genes, or contributors to cancer progression. Of 
note, MDM2 was found to be down-regulated in the intravenous leiomyomatosis cases, 
supporting further the negative immunohistochemistry results for MDM2 (see 
Supplementary Table).
DISCUSSION
Intravenous leiomyomatosis is a histologically benign smooth muscle tumor, developing 
within the uterine and pelvic veins, that extends in severe cases into the inferior vena cava 
and chambers of the right heart (10–12). Similar to uterine leiomyoma, intravenous 
leiomyomatosis is composed of a bland proliferation of fascicles of smooth muscle, and in 
many cases, is associated with a typical uterine leiomyoma on pathologic examination. 
Although an uncommon phenomenon, analyzing the molecular mechanisms of intravenous 
leiomyomatosis may provide valuable insights into the histological events that underlie the 
transition from a non-invasive uterine leiomyoma to an invasive intravenous leiomyomatosis.
Chromosomal rearrangements at 12q14-15 are frequent in various mesenchymal tumors 
including breast fibroadenoma, cutaneous lipoma, pulmonary chondroid hamartoma, 
salivary gland pleomorphic adenoma, vulvar aggressive angiomyxoma, and uterine 
leiomyoma (3, 34–39). It is well established that these rearrangements are clustered around a 
genomic region that includes HMGA2 (formerly HMGIC, 12q14.3), as well as MDM2 
(12q15) and CDK4 (12q14.1) (20, 32, 36, 40). Also, overexpression of HMGA2, MDM2, 
and CDK4 proteins associated with these chromosomal alterations has been shown in some 
mesenchymal tumors including Müllerian adenosarcoma (20, 41, 42). MDM2 and CDK4 
proto-oncogenes have an important role in permitting override of the G1-S cell cycle 
checkpoint, and up-regulation of these genes leads to increased cell proliferation and 
survival (43–45). HMGA2 is a non-histone DNA architectural factor involved in 
transcriptional regulation that likely affects a variety of downstream targets involved in 
differentiation and proliferation (46–48). It plays a role in normal mesenchymal growth, and 
developmental perturbations result in abnormal fat and skeletal changes determining overall 
adiposity and height in both mice and humans (32, 47, 49–51). The genetic alteration 
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leading to the downstream effect of HMGA2 expression varies among the aforementioned 
mesenchymal tumors (42, 52–54). For example, fusion gene formation predominates in 
lipomas resulting in translocation of the three AT-hook DNA binding domains of HMGA2 to 
a variety of chromosome partners (36), whereas in uterine leiomyoma the chromosomal 
aberration 5′ of the HMGA2 locus is preferentially a translocation between chromosomes 
12 and 14. HMGA2 coding sequence remains almost uniformly intact with dysregulated 
HMGA2 expression, presumably due to either a transposition of a promoter or positive 
regulatory element on chromosome 14 adjacent to HMGA2 on chromosome 12, or removal 
of a negative regulatory element from chromosome 12 (55).
The present study analyzed expression of HMGA2, MDM2, and CDK4 proteins in 12 
intravenous leiomyomatosis cases based on the previous finding of der(14)t(12;14)(q15;q24) 
in intravenous leiomyomatosis (18, 19). The frequency of HMGA2 protein expression in 
intravenous leiomyomatosis (58%) was higher than that reported in uterine leiomyoma 
(32%) (56); MDM2 and CDK4 expression was not detected in any cases. These findings 
suggest that HMGA2 protein expression might contribute to the underlying mechanisms for 
intravenous leiomyomatosis development, particularly considering similar results reported 
for uterine leiomyoma, plexiform leiomyomata, vulvar aggressive angiomyxoma, and other 
mesenchymal tumors (20, 32, 35, 42, 57–59), in addition to a potential role of HMGA2 as a 
tumor driver for metastasis and invasion (50, 60, 61).
Only Case 1 was suitable for GTG-banded karyotyping and metaphase FISH analyses in 
addition to the previously published Cases 2 and 3 (18, 19). Cases 1 and 2 showed loss of 
chromosome 22 consistent with a recent publication reporting aCGH in nine intravenous 
leiomyomatosis cases with deletions of 22 as the most frequent aberration (66.7%) (62). 
Case 1 had an interstitial deletion of the 12q14.3 region leading to loss of HMGA2 at this 
site concurrent with co-amplification of HMGA2 on the long arm of chromosome 14, 
consistent with interphase FISH results (Tables 1 and 2, Fig. 2). The aCGH result for Case 3 
supported further the replacement of a chromosome 14 with a der(14)t(12;14) with loss of 
the 14q24->14qter region. To assess cytogenetic correlation with HMGA2 protein 
expression, interphase FISH was performed on intravenous leiomyomatosis cases using 
probes for both HMGA2 and 14q24 loci. All of the analyzed HMGA2-positive cases (five 
out of seven) had hybridization patterns with co-localization of the probes. Three cases had 
more than two hybridization signals for HMGA2. Overall, based on the high frequency 
(89.2%, 95% confidence interval: 83.8–94.6%) of co-localization of FISH signals in 
HMGA2-positive cases compared to that of HMGA2-negative cases (12.4%) and the 
relatively lower frequency of supernumerary HMGA2 copies, the t(12;14) leading to 
HMGA2 expression might be considered as the primary pathogenetic event, and acquisition 
of extra HMGA2 copies a secondary, but not necessarily critical event in intravenous 
leiomyomatosis pathogenesis. This finding is further supported by the aforementioned 
intravenous leiomyomatosis microarray study reporting amplification of the HMGA2 locus 
in only two out of nine cases (22%) (62). We propose that loss of der(12)t(12;14) followed 
by reduplication of an apparently normal copy of chromosome 12 (resulting in three copies 
of HMGA2 or, alternatively, potential loss of heterozygosity on chromosomes 12 and 14) 
might play a role in the pathogenesis of intravenous leiomyomatosis. Interphase FISH was 
also performed for evaluating presence of a deletion of 7q, the most common cytogenetic 
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finding in uterine leiomyoma (24); none of the cases showed loss of hybridization signal for 
the 7q22 probe, further highlighting the role of HMGA2 in intravenous leiomyomatosis 
pathogenesis.
Emerging evidence suggests at least four molecular subclasses for uterine leiomyoma: 
MED12 mutation, FH inactivation, HMGA2 overexpression, and COL4A6–COL4A5 
deletion. MED12 and HMGA2 aberrations are found to be mutually exclusive with very 
distinct gene expression profiles, suggesting two separate pathways of uterine leiomyoma 
formation. Taken together, they may account for 80%–90% of all uterine leiomyoma cases. 
Chromosome 7q alterations have been reported to co-occur with both MED12 and HMGA2 
aberrations, indicating a secondary event in uterine leiomyoma pathogenesis (63, 64). The 
absence of MED12 mutations in previously reported intravenous leiomyomatosis cases (62) 
and the lack of 7q deletion detection in the current study, provide further evidence for the 
resemblance of intravenous leiomyomatosis to uterine leiomyoma with HMGA2 aberrations 
and the role of HMGA2 in the primary pathogenesis of intravenous leiomyomatosis.
Rearrangements of 12q14-15, typically t(12;14)(q14.3;q24), occur in approximately 7.5% of 
all uterine leiomyoma and 20% of karyotypically abnormal uterine leiomyoma (65). It has 
been shown that the presence of t(12;14) in uterine leiomyoma leads to elevated expression 
of HMGA2 (25, 57–59). Also, uterine leiomyoma with rearrangements of 12q14-15 are 
larger in size than those with either interstitial 7q22 deletions or normal karyotypes (66, 67), 
suggesting a marked growth advantage of cells with dysregulated HMGA2. Tumor size 
might be directly related to increased expression of HMGA2, which has been identified as a 
delayed early response gene promoting progression to S phase in response to growth factors 
in various cell types, by overcoming the requirement for mitogenic stimulation (68–71).
Intravenous leiomyomatosis is usually considered together with a group of tumors including 
disseminated peritoneal leiomyomatosis and benign metastasizing leiomyoma, which 
resemble uterine leiomyoma at both gross and microscopic levels but are found in unusual 
anatomical locations. A common molecular mechanism underlying these tumors might help 
to understand better intravenous leiomyomatosis pathogenesis, as well as the malignant 
potential of some uterine leiomyomata. In that regard, a study analyzing a disseminated 
peritoneal leiomyomatosis case occurring after laparoscopic morcellation for uterine 
leiomyoma was observed to have a t(12;14)(q15;q24), del(3)(q23q26.33), and r(1)
(p34.3q41), all of which are characteristic cytogenetic findings of uterine leiomyoma (30). 
Like the findings of the current study, deletion of 7q22 was not detected in this disseminated 
peritoneal leiomyomatosis case. Another study analyzing a paratesticular leiomyoma 
reported a karyotype of 46,XY,der(5)t(5;14)(q31;q24),der(14)t(12;14)(q15;q24)[25] with 
HMGA2 over-expression providing further evidence for the importance of HMGA2 and 
t(12;14) in the pathogenesis of the unusual variants of uterine leiomyoma (72).
Vulvar aggressive angiomyxoma also have frequent aberrant HMGA2 expression due to 
12q14-15 rearrangements. Although not observed to metastasize or invade vessels, this 
vulvar mesenchymal neoplasm is locally and destructively invasive. In contrast to uterine 
leiomyoma and intravenous leiomyomatosis, a wide range of translocation partners are 
observed in aggressive angiomyxomas (35, 73–75). Müllerian adenosarcomas of the uterus 
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have frequent amplification of 12q that leaves HMGA2 intact and leads to over-expression 
(42). The molecular basis by which the malignant phenotypes of these tumors is determined 
remains to be elucidated, but is presumably superimposed upon the effect of aberrant 
HMGA2 expression.
Despite the common properties of intravenous leiomyomatosis and uterine leiomyoma at 
both histopathologic and cytogenetic levels as described above, uterine leiomyoma is 
considered benign whereas intravenous leiomyomatosis has a quasi-malignant behavior 
characterized by prominent vascular invasion. Another possible mechanism that might 
explain the different phenotype is the state of the cell in which HMGA2 dysregulation 
occurs (76). This phenomenon is identified as “the cell of origin effect”. If the founder cell 
transformed in intravenous leiomyomatosis is different than uterine leiomyoma, it might be 
morphologically similar, but have a different biologic potential supported by the result of the 
cluster analysis with the closer relationship of intravenous leiomyomatosis to 
leiomyosarcoma in the current study. Although differences in transcription profiles between 
uterine leiomyoma and intravenous leiomyomatosis may provide a molecular explanation 
for vascular invasiveness, a clear indication of key genes that would explain this difference 
in phenotype was not readily apparent in our analysis, although there are some suggestive 
genes (Supplementary Table). Of potential relevance, it should be noted that despite the 
common t(12;14) abnormality, intravenous leiomyomatosis cases also had additional 
chromosomal abnormalities detected by GTG-banded karyotyping and aCGH (Tables 1 and 
2), which might contribute to the unusual behavior of intravenous leiomyomatosis. Further 
study is warranted to delineate the molecular mechanism(s) underlying the intravenous 
leiomyomatosis phenotype.
In conclusion, the significant association detected between HMGA2 expression and t(12;14)
(q15;q24) in intravenous leiomyomatosis cases is likely to play an important role in 
intravenous leiomyomatosis tumorigenesis, but the quasi-malignant behavior of intravenous 
leiomyomatosis might be attributed to additional genetic alterations as suggested by 
transcriptional and aCGH analyses.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
(A) Hematoxylin and eosin stained tissue section of Case 1 shows a plug-like tumor mass 
nearly occluding the residual cleft-like endothelial-lined vascular lumen with normal 
myometrium on the right. (B) Immunohistochemistry with a polyclonal HMGA2 antibody 
showing strong staining in intravenous leiomyomatosis tissue, but not in the adjacent 
myometrium. (C) Higher magnification image of panel B, in which one can appreciate that 
the HMGA2 staining is specific to nuclei in smooth muscle cells in lesional cells, but not in 
endothelial cells or smooth cells in the supporting normal blood vessels and adjacent 
myometrium.
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Fig. 2. 
Partial GTG-banded karyotype, metaphase and interphase FISH of Case 1. Partial karyotype 
(top) shows a chromosome 12, del(12), chromosome 14 and der(14). In the metaphase FISH 
(middle), absence of hybridization of both HMGA2 probes (5′ green and 3′ orange) is 
observed on the del(12) whereas amplification of the 3′ HMGA2 (orange) is detected on the 
der(14). In the interphase FISH (bottom) the absence of 3′ HMGA2 signal (green, 5′ 
HMGA2 not performed) is observed and its amplification is detected on the der(14) next to 
the 14q24 signal (orange).
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Fig. 3. 
Representative image for co-localization of hybridization signals of BAC probes 
RP11-366L20 at 12q14.3 (green), spanning the 3′ HMGA2, and RP11-195L9 at 14q24.1 
(orange) in Case 4.
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Fig. 4. 
Hierarchical clustering of mRNA expression profiling of three cases of intravenous 
leiomyomatosis (IVL) compared to the profiles of leiomyosarcoma (LMS), leiomyoma of 
the usual histologic type (LEIO), histologic variants of leiomyomata (cellular, atypical and 
plexiform), and myometrium (MYO).
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Fig. 5. 
Differentially expressed genes (p<0.05) in three intravenous leiomyomatosis cases (IVL) in 
comparison to uterine leiomyomata with t(12;14) (T1 to T9) (red: up-regulated, blue: down-
regulated).
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Table 1
GTG-banded karyotype and metaphase FISH characterization of intravenous leiomyomatosis cases
Case No. Karyotype Metaphase FISH interpretation
1 45,XX,del(12)(q?14q?15),hsr(14)(q2?1),-22[7].ishdel(12)(q14.3q14.3)(5′HMGA2-,3′HMGA2-),hsr(14)amp(3′HMGA2)
HMGA2 amplification on 
abnormal 14q, breakpoint 5′ 
(centromeric) to 3′HMGA2
21 45,XX,der(14)t(12;14)(q15;q24),-22.ishder(14)t(12;14) (RAD51L1+,5′HMGA2+,3′HMGA2+)
3 copies of HMGA2, breakpoint 
5′ (centromeric) to HMGA2
32 45,XX,-10,add(11)(q11),der(14)t(12;14)(q15;q24)[12]/45,XX,-10,add(11)(q11),t(12;14)(q15;q24)[3].ishder(14)t(12;14)(5′HMGA2+,3′HMGA2+)/t(12;14)(5′HMGA2-,3′HMGA2-;5′HMGA2+,3′HMGA2+)
Mosaic karyotype with 3 and 2 
copies of HMGA2, breakpoint 5′ 
(centromeric) to HMGA2
1
Previously published as ST00-142 (19)
2
Previously published as ST02-0165 (18)
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Table 2
HMGA2 immunohistochemistry and HMGA2 interphase FISH analysis
Case no.1 HMGA2 expression by immunohistochemistry
% nuclei with HMGA2 and 14q24 probe co-localization by interphase 
FISH2
1 Positive (+4) 823
2 Positive (+4) 944
3 Positive (+4) Not Determined5
4 Positive (+4) 90
5 Positive (+4) 906
6 Positive (+4) Not Determined
7 Positive (+4) 90
8 Negative (0) 14
9 Negative (0) 13
10 Negative (0) 16
11 Negative (0) 9
12 Negative (0) 10
1Cases ordered by HMGA2 immunohistochemistry expression status
2When grouped by immunohistochemistry expression status, the mean percentages of FISH probe co-localization were significantly different 
(p=8.24×10−10): 89.2% (95% confidence interval: 83.8–94.6%) vs. 12.4% (95% confidence interval: 8.8–16.0%) for cases with positive and 
negative HMGA2 protein expression, respectively.
3
Interphase FISH showed HMGA2 amplification in 96/100 nuclei.
4
Interphase FISH showed that 69/100 nuclei had three hybridization signals for HMGA2, and was previously reported as ST00-142 to have 
der(14)t(12;14)(q15;q24) and three hybridization signals for HMGA2 in metaphase FISH (Table 1, published as ST00-142) (19).
5
Previously reported to have der(14)t(12;14)(q15;q24) and three hybridization signals for HMGA2 in metaphase FISH (Table 1, published as 
ST02-165) (18).
6
Interphase FISH showed that 20/100 nuclei had three hybridization signals for HMGA2.
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